⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28045839 | 0.86 | — | — | |
| SCHEMBL3947045 | 0.84 | ALDH1A1 (0.96) | — | |
| SCHEMBL28442719 | 0.82 | ALDH1A1 (1.00) | — | |
| SCHEMBL8386922 | 0.82 | ALDH1A1 (1.00) | — | |
| SCHEMBL8308804 | 0.77 | — | — | |
| SCHEMBL15791181 | 0.77 | — | — | |
| SCHEMBL11324040 | 0.75 | TSHR (0.48) | — | |
| SCHEMBL21261846 | 0.75 | — | — | |
| SCHEMBL442562 | 0.75 | — | — | |
| SCHEMBL13938722 | 0.75 | MAPT (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685195-A1 | DEGRADABLE CROSSLINKING AGENT | NAGASE CHEMTEX CORPORATION (JP) | 2026-01-28 | — | — | EP | disclosed |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025028637-A1 | DEGRADABLE COMPOUND | ナガセケムテックス株式会社 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025028636-A1 | DEGRADABLE CROSSLINKING AGENT | ナガセケムテックス株式会社 | 2025-02-06 | — | — | WO | disclosed |
| EP-4476230-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| WO-2024195687-A1 | DEGRADABLE CROSSLINKING AGENT | ナガセケムテックス株式会社 | 2024-09-26 | — | — | WO | disclosed |
| CN-117916269-A | Method for preventing aggregation of proteins | 真和制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| CN-117897406-A | anti-GAL 3 antibodies and methods for their use in insulin resistance | 真和制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-2027144-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-02-25 | — | — | EP | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007131966-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| US-6153628-A | 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as αv β3 antagonists | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| EP-1049693-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999026945-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |